DNA icon

Usher Syndrome Panel

Summary and Pricing

Test Method

Exome Sequencing with CNV Detection
Test Code Test Copy Genes Gene CPT Codes Copy CPT Codes
ADGRV1 81479,81479
ARSG 81479,81479
CDH23 81408,81479
CIB2 81479,81479
CLRN1 81404,81479
MYO7A 81407,81479
PCDH15 81407,81406
PDZD7 81479,81479
USH1C 81407,81479
USH1G 81404,81479
USH2A 81408,81479
WHRN 81479,81479
Test Code Test Copy Genes Panel CPT Code Gene CPT Codes Copy CPT Code Base Price
10053Genes x (12)81479 81404(x2), 81406(x1), 81407(x3), 81408(x2), 81479(x16) $990 Order Options and Pricing

Pricing Comments

We are happy to accommodate requests for testing single genes in this panel or a subset of these genes. The price will remain the list price. If desired, free reflex testing to remaining genes on panel is available. Alternatively, a single gene or subset of genes can also be ordered via our Custom Panel tool.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).

Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Ben Dorshorst, PhD

Clinical Features and Genetics

Clinical Features

Usher syndrome is a clinically heterogeneous genetic disorder that is characterized by progressive retinitis pigmentosa (RP), sensorineural hearing impairment, and in some cases, vestibular abnormalities. Features of RP include night blindness progressing to constriction of the peripheral visual field with eventual loss of central vision, abnormal fundus with bone-spicule deposits/attenuated retinal vessels, and abnormal electroretinographic (ERG) findings (Daiger et al. 2007). Vestibular abnormalities often result in development delay in sitting and walking. Three clinical subtypes of Usher syndrome are currently recognized based on the age of onset, severity of symptoms, and vestibular involvement, although there is considerable variability within a subtype thus resulting in overlapping symptoms between subtypes. Usher syndrome type 1 (USH1) is the most common type and is distinguished by severe to profound congenital hearing loss, RP beginning in childhood, and abnormal vestibular function (Ahmed et al. 2013). Usher syndrome type 2 (USH2) involves moderate to severe hearing impairment, late-onset RP, and normal vestibular function. Usher syndrome type 3 (USH3) is characterized by progressive hearing loss and variable age of onset for retinal degeneration. The prevalence of Usher syndrome in the United States is 1 in 6,000 (Kimberling et al. 2010).


Sequence variants in one of 12 genes cause Usher syndrome, a clinically heterogeneous autosomal recessive disorder (Bolz and Roux 2011; Khateb et al. 2018. PubMed ID: 29300381). USH1 is caused by pathogenic sequence variants in the following genes: cadherin-related family, member 23 (CDH23), which encodes for a 3,354-amino acid calcium ion-dependent transmembrane adhesion protein that contains ankyrin repeats; calcium- and integrin-binding protein 2 (CIB2), which encodes a calcium-binding actin-based protein that mediates intracellular calcium signaling; myosin VIIA (MYO7A), which encodes unconventional myosins with structurally conserved heads that move along actin filaments; protocadherin 15 (PCDH15), which encodes a 1,955-amino acid calcium ion-binding protein that contains 11 cadherin repeats and two domains that are proline-rich; Usher syndrome type 1C (USH1C), which encodes a 652-amino acid PDZ domain-containing protein called harmonin that is predominantly expressed in the sensory hair cells of the inner ear; and Usher syndrome type 1G (USH1G), which encodes a scaffold protein containing ankyrin repeats and a sterile alpha motif (SAM) called sans that is expressed in the cochlea (Ahmed et al. 2001; Riazuddin et al. 2012; Blanco-Sanchez et al. 2014).

USH2 is caused by causative sequence variants in the following genes: deafness, autosomal recessive 31 (WHRN), which encodes a PDZ domain-containing protein called whirlin that contains actin polymerization and the growth of stereocilia in the inner ear; G protein-coupled receptor 98 (GPR98), which encodes a 326-amino acid protein that is involved in neurotransmission and in the formation of synaptic contacts; PDZ domain-containing 7 (PDZD7), which encodes a binding protein that is expressed in the mechanosensory hair cells of the inner ear; and Usher syndrome type 2a (USH2A), which encodes a 1,551-amino acid protein that acts as a component of the basal lamina and extracellular matrices of the ears and eyes (Yang et al. 2010; Garcia-Garcia et al. 2013; Zou et al. 2014).

USH3 is caused by pathogenic sequence variants the clarin 1 (CLRN1) gene, which encodes a 232-amino acid transmembrane protein that is expressed in the inner and outer hair cells of the organ of Corti and the spiral ganglion cells; it possesses mechanotransduction channel activity and assists in the proper localization of synaptic components (Ogun and Zallocchi 2014).

The mutational spectrum of the 12 genes implicated in Usher syndrome mainly include missense, nonsense, and splicing sequence variants, as well as some small deletions, duplications, and insertions. The most common sequence variants that have been reported as pathogenic for Usher syndrome occur in the following genes: USH2A, MYO7A, CDH23, GPR98, and PCDH15. On the other hand, only a few pathogenic sequence variants have been reported for the USH1C, CLRN1, USH1G, WHRN, CIB2, and PDZD7 genes (Stenson et al. 2003).

Pathogenic variants in ARSG have been associated with autosomal recessive Usher syndrome type 4, with later onset than other forms of Usher syndrome in the fourth decade or later (Khateb et al. 2018. PubMed ID: 29300381; Abad-Morales et al. 2020. PubMed ID: 32455177; Fowler et al. 2021. PubMed ID: 33629623; Peter et al. 2021. PubMed ID: 33300174; Velde et al. 2022. PubMed ID: 35226187).

Clinical Sensitivity - Sequencing with CNV PGxome

Pathogenic variants in the genes in this NextGen panel may be responsible for 11.3% to 91% of Usher syndrome cases, depending on the combination of genes utilized in the NextGen assay and the specific population being screened. A German study that performed sequencing of 9 genes showed that all 42 Usher syndrome patients (100%) harbored causative sequence variants (Krawitz et al. 2014). In a French study that involved sequencing of 9 genes, 49 out of 54 (91%) Usher syndrome patients showed pathogenic sequence variants (Bonnet et al. 2011). On the other hand, a Spanish study that conducted sequencing of 10 genes reported that 22 out of 32 (69%) Usher syndrome patients tested positive for causative pathogenic sequence variants (Aparisi et al. 2014). A US-based study that performed sequencing of 5 genes showed that 15 out of 133 (11.3%) hard-of-hearing or deaf pediatric patients harbored pathogenic sequence variants (Kimberling et al. 2010).

Large-scale copy number variants may be responsible for around 6% of Usher syndrome alleles. The most frequent CNVs have been detected in the USH2A, MYO7A, CDH23, GPR98, and PCDH15 genes (Stenson et al. 2003).

Testing Strategy

This test is performed using Next-Gen sequencing with additional Sanger sequencing as necessary.

This panel typically provides 99.9% coverage of all coding exons of the genes plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define coverage as ≥20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).

Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).

Indications for Test

Patients with combined congenital sensorineural hearing loss, RP, and vestibular areflexia.


Official Gene Symbol OMIM ID
ADGRV1 602851
ARSG 610008
CDH23 605516
CIB2 605564
CLRN1 606397
MYO7A 276903
PCDH15 605514
PDZD7 612971
USH1C 605242
USH1G 607696
USH2A 608400
WHRN 607928
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Related Test



  • Abad-Morales et al. 2020. PubMed ID: 32455177
  • Ahmed et al. 2013. PubMed ID: 24022220
  • Aparisi et al. 2014. PubMed ID: 25404053
  • Blanco-Sánchez et al. 2014. PubMed ID: 24626987
  • Bolz and Roux. 2011. PubMed ID: 21697857
  • Bonnet et al. 2011. PubMed ID: 21569298
  • Daiger et al. 2007. PubMed ID: 17296890
  • Fowler et al. 2021. PubMed ID: 33629623
  • García-García et al. 2013. PubMed ID: 23441107
  • Khateb et al. 2018. PubMed ID: 29300381
  • Kimberling et al. 2010. PubMed ID: 20613545
  • Krawitz et al. 2014. PubMed ID: 25333064
  • Ogun and Zallocchi. 2014. PubMed ID: 25365995
  • Peter et al. 2021. PubMed ID: 33300174
  • Riazuddin et al. 2012. PubMed ID: 23023331
  • Stenson et al. 2003. PubMed ID: 12754702
  • Velde et al. 2022. PubMed ID: 35226187
  • Yang et al. 2010. PubMed ID: 20502675
  • Zou et al. 2014. PubMed ID: 24334608


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

PGxome (Exome) Sequencing Panel

PGnome (Genome) Sequencing Panel

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard